Fate Therapeutics Inc (NASDAQ: FATE) stock closed at $3.82 on 9/10/24 after a major increase of 10.7%. However, trading volume in this advance was unusually low at 54% of normal. The stock has been weak relative to the market over the last nine months but has risen 4.1% during the last week.
Current PriceTarget Research Rating
FATE’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to be Value Creation neutral.
Fate Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Fate Therapeutics has a slightly negative Appreciation Score of 39 and a poor Power Rating of 16, producing the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment